Paul Hutson, a professor at the University of Wisconsin-Madison who studies psilocybin and leads the school’s center for psychedelics research, said he anticipates within the next five years there will be enough evidence for the FDA to approve MDMA and psilocybin to treat PTSD and depression.
University Communications